These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 23624870

  • 1. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay L, Zarandi M, Ortmann O, Engel JB, Buchholz S.
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L, Arenas MI, Schally AV, Fernández-Martínez AB, Zarka E, González-Santander M, Carmena MJ, Vacas E, Prieto JC, Bajo AM.
    Int J Cancer; 2013 Feb 15; 132(4):755-65. PubMed ID: 22777643
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A, Schally AV, Halmos G, Varga JL, Seitz S, Buchholz S, Rick F, Zarandi M, Bellyei S, Treszl A, Szalontay L, Lucci JA.
    Horm Metab Res; 2011 Oct 15; 43(11):816-20. PubMed ID: 22009378
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
    Zhao L, Yano T, Osuga Y, Nakagawa S, Oishi H, Wada-Hiraike O, Tang X, Yano N, Kugu K, Schally AV, Taketani Y.
    Int J Oncol; 2008 Mar 15; 32(3):593-601. PubMed ID: 18292936
    [Abstract] [Full Text] [Related]

  • 6. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M, Varga JL.
    Prostate; 2008 Dec 01; 68(16):1763-72. PubMed ID: 18729085
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
    Seitz S, Hohla F, Schally AV, Moder A, Engel JB, Horn F, Varga J, Zarandi M, Ortmann O, Köster F, Buchholz S.
    Oncol Rep; 2008 Nov 01; 20(5):1289-94. PubMed ID: 18949435
    [Abstract] [Full Text] [Related]

  • 8. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
    Pozsgai E, Schally AV, Hocsak E, Zarandi M, Rick F, Bellyei S.
    Int J Oncol; 2011 Oct 01; 39(4):1025-32. PubMed ID: 21701777
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.
    Schally AV, Wang H, He J, Cai R, Sha W, Popovics P, Perez R, Vidaurre I, Zhang X.
    Proc Natl Acad Sci U S A; 2018 Nov 20; 115(47):12028-12033. PubMed ID: 30373845
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
    Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Busto R, Halmos G.
    J Clin Endocrinol Metab; 2001 May 20; 86(5):2144-52. PubMed ID: 11344219
    [Abstract] [Full Text] [Related]

  • 15. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.
    Köster F, Engel JB, Schally AV, Hönig A, Schröer A, Seitz S, Hohla F, Ortmann O, Diedrich K, Buchholz S.
    Breast Cancer Res Treat; 2009 Jul 20; 116(2):273-9. PubMed ID: 18629632
    [Abstract] [Full Text] [Related]

  • 16. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M.
    Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342
    [Abstract] [Full Text] [Related]

  • 17. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
    Szalontay L, Schally AV, Popovics P, Vidaurre I, Krishan A, Zarandi M, Cai RZ, Klukovits A, Block NL, Rick FG.
    Cell Cycle; 2014 Aug 01; 13(17):2790-7. PubMed ID: 25486366
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG, Schally AV, Block NL, Abi-Chaker A, Krishan A, Szalontay L.
    Prostate; 2013 Jun 01; 73(8):873-83. PubMed ID: 23280565
    [Abstract] [Full Text] [Related]

  • 19. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
    Kahán Z, Varga JL, Schally AV, Rékási Z, Armatis P, Chatzistamou L, Czömpöly T, Halmos G.
    Breast Cancer Res Treat; 2000 Mar 01; 60(1):71-9. PubMed ID: 10845811
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.